ACRP Expands Credentialing Program for Clinical Trial Investigators
ACRP announced changes to its investigator certification program
The Academy of Clinical Research Professionals today announced changes to its investigator certification program that will allow for broader credentialing of those performing the pivotal role of principal investigator in clinical trials.
The Academy Board of Trustees voted to change the eligibility criteria for its Certified Physician Investigator (CPI) program to allow for individuals with a doctorate-level degree, such as PhD, Pharm.D, DNP, to earn recognition of their clinical research-specific expertise through certification. The CPI program had previously been open only to individuals holding an active medical license.
As part of its expansion of the CPI program's eligibility criteria, the Academy Board also approved a program title change from Certified Physician Investigator to Certified Principal Investigator.
Applicants for the CPI program are still required to demonstrate active participation in the clinical trials process, but are no longer required to hold a current license to practice medicine.
"Because the CPI® program is designed to focus on the clinical research-specific competencies required of a clinical trial investigator, not medical knowledge, this change is more reflective of the scope and diversity of investigators involved in the clinical research process," says Deborah L. Rosenbaum, CCRC, CCRA, Academy Chair. "The changes announced today also provide greater standardization of the knowledge, skills, and abilities that can be expected from a certified individual performing the role of the investigator in clinical research."
ACRP is the only organization offering role-specific certification programs for clinical research professionals through its Certified Clinical Research Coordinator (CCRC), Certified Clinical Research Associate (CCRA), and Certified Principal Investigator (CPI) programs, all of which hold the distinction of being the only clinical research certification programs accredited by the National Commission for Certifying Agencies.
TransCelerate BioPharma recognizes ACRP's CCRC, CCRA, and CPI designations as evidence of Good Clinical Practice training, and American Nurses Credentialing Center recognizes ACRP's CCRC and CCRA designations toward assisting a hospital in meeting requirements of its Magnet Recognition Program.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Empower Sponsor Success with Insights from Sites
October 3rd 2024Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.
Tulisokibart Shows Superior Efficacy in Achieving Clinical Remission for Ulcerative Colitis Patients
October 2nd 2024Proof-of-concept Phase II ARTEMIS-UC trial shows efficacy of investigational humanized monoclonal antibody tulisokibart in treating inflammatory bowel disease compared with placebo.
